EXFO, EXFO Inc.
EXFO designs, manufactures, and markets test and service assurance solutions for network service providers (NSPs) and equipment manufacturers in the telecommunications industry worldwide.
EXFO's Telecom division principally offers AXS-200 SharpTESTER, a multi-service, multi-medium handheld test platform for characterizing and troubleshooting commercial and residential access networks; FTB-200 Compact Platform, a two-slot portable test unit for multi-technology, multi-application characterization of metro and access networks; FTB-500 that provides NSPs with a way to perform multiple, advanced test operations for installation, maintenance, and troubleshooting applications; and IQS-600 platform for manufacturing, and research and development applications.
EXFO's Life Sciences and Industrial division provides solutions in medical-device and opto-electronics assembly, fluorescence microscopy, and other life sciences sectors.
** EXFO reported record sales and bookings as well as strong earnings for its 25th fiscal year ended August 31, 2010.
- Annual sales increase 32.0% to record US$228.1 million
- Gross margin* improves for eighth consecutive year to reach 62.4%
- EBITDA increases 88.8% year-over-year to US$27.3 million
- NetHawk acquisition expands presence in wireless testing and service assurance
More about EXFO at www.exfo.com
TTNP, Titan Pharmaceuticals, Inc., TTNP.OB
TTNP is a biopharmaceutical company with valuable assets in the CNS (central nervous system) area.
On May 6, 2009 Fanapt™, an atypical antipsychotic drug, was granted marketing approval by the US Food & Drug Administration for the treatment of adult patients with schizophrenia. TTNP is entitled to receive 8-10% royalties on global net sales of Fanapt™.
The global sales of atypical antipsychotic products exceeds $20 billion per year.
Probuphine is an innovative, subcutaneous implant formulation designed using TTNP's proprietary ProNeura™ technology to deliver a steady, round-the-clock low dose of the marketed drug buprenorphine over six months following a single treatment.
This product is in Phase 3 development and has already demonstrated strong positive results in a controlled Phase 3 study for the treatment of opioid addiction.
** TTNP reported that data from its previously completed and announced Phase 3 randomized, placebo-controlled clinical trial of Probuphine were published in the Journal of the American Medical Association (JAMA).
The article highlights data from the 163-patient trial, which showed that patients receiving TTNP's Probuphine implant had significantly less illicit opioid use, experienced fewer symptoms of withdrawal and craving, stayed in treatment longer and had greater overall improvement when compared to placebo patients over the course of the 24-week study.
The publication, "Buprenorphine Implants for Opioid Dependence: A Randomized Controlled Trial" will appear in the October 13, 2010 issue of the Journal of the American Medical Association.
The World Health Organization estimates that 2.8 million individuals in the U.S. and Europe are addicted to illicit opiates such as heroin, and more than 2.0 million individuals in the U.S. alone are addicted to prescription opioid medications. It is estimated that about 20 percent of this population are currently receiving pharmacological treatment.
More about TTNP at www.titanpharm.com
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://crwefinance.com/disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.